TY - JOUR
T1 - Increasing Racial and Ethnic Diversity in Cancer Clinical Trials
T2 - An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement
AU - Oyer, Randall A.
AU - Hurley, Patricia
AU - Boehmer, Leigh
AU - Bruinooge, Suanna Steeby
AU - Levit, Kathryn
AU - Barrett, Nadine
AU - Benson, Al
AU - Bernick, Lea Ann
AU - Byatt, Leslie
AU - Charlot, Marjory
AU - Crews, Jennie
AU - Deleon, Kyle
AU - Fashoyin-Aje, Lola
AU - Garrett-Mayer, Elizabeth
AU - Gralow, Julie R.
AU - Green, Sybil
AU - Guerra, Carmen E.
AU - Hamroun, Leila
AU - Hardy, Claudia M.
AU - Hempstead, Bridgette
AU - Jeames, Sanford
AU - Mann, Mel
AU - Matin, Khalid
AU - Mccaskill-Stevens, Worta
AU - Merrill, Janette
AU - Nowakowski, Grzegorz S.
AU - Patel, Manali I.
AU - Pressman, Alice
AU - Ramirez, Amelie G.
AU - Segura, Juanita
AU - Segarra-Vasquez, Barbara
AU - Hanley Williams, Jen
AU - Williams, James E.
AU - Winkfield, Karen M.
AU - Yang, Eddy S.
AU - Zwicker, Victoria
AU - Pierce, Lori J.
N1 - Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - A concerted commitment across research stakeholders is necessary to increase equity, diversity, and inclusion (EDI) and address barriers to cancer clinical trial recruitment and participation. Racial and ethnic diversity among trial participants is key to understanding intrinsic and extrinsic factors that may affect patient response to cancer treatments. This ASCO and Association of Community Cancer Centers (ACCC) Research Statement presents specific recommendations and strategies for the research community to improve EDI in cancer clinical trials. There are six overarching recommendations: (1) clinical trials are an integral component of high-quality cancer care, and every person with cancer should have the opportunity to participate; (2) trial sponsors and investigators should design and implement trials with a focus on reducing barriers and enhancing EDI, and work with sites to conduct trials in ways that increase participation of under-represented populations; (3) trial sponsors, researchers, and sites should form long-standing partnerships with patients, patient advocacy groups, and community leaders and groups; (4) anyone designing or conducting trials should complete recurring education, training, and evaluation to demonstrate and maintain cross-cultural competencies, mitigation of bias, effective communication, and a commitment to achieving EDI; (5) research stakeholders should invest in programs and policies that increase EDI in trials and in the research workforce; and (6) research stakeholders should collect and publish aggregate data on racial and ethnic diversity of trial participants when reporting results of trials, programs, and interventions to increase EDI. The recommendations are intended to serve as a guide for the research community to improve participation rates among people from racial and ethnic minority populations historically under-represented in cancer clinical trials. ASCO and ACCC will work at all levels to advance the recommendations in this publication.
AB - A concerted commitment across research stakeholders is necessary to increase equity, diversity, and inclusion (EDI) and address barriers to cancer clinical trial recruitment and participation. Racial and ethnic diversity among trial participants is key to understanding intrinsic and extrinsic factors that may affect patient response to cancer treatments. This ASCO and Association of Community Cancer Centers (ACCC) Research Statement presents specific recommendations and strategies for the research community to improve EDI in cancer clinical trials. There are six overarching recommendations: (1) clinical trials are an integral component of high-quality cancer care, and every person with cancer should have the opportunity to participate; (2) trial sponsors and investigators should design and implement trials with a focus on reducing barriers and enhancing EDI, and work with sites to conduct trials in ways that increase participation of under-represented populations; (3) trial sponsors, researchers, and sites should form long-standing partnerships with patients, patient advocacy groups, and community leaders and groups; (4) anyone designing or conducting trials should complete recurring education, training, and evaluation to demonstrate and maintain cross-cultural competencies, mitigation of bias, effective communication, and a commitment to achieving EDI; (5) research stakeholders should invest in programs and policies that increase EDI in trials and in the research workforce; and (6) research stakeholders should collect and publish aggregate data on racial and ethnic diversity of trial participants when reporting results of trials, programs, and interventions to increase EDI. The recommendations are intended to serve as a guide for the research community to improve participation rates among people from racial and ethnic minority populations historically under-represented in cancer clinical trials. ASCO and ACCC will work at all levels to advance the recommendations in this publication.
UR - http://www.scopus.com/inward/record.url?scp=85132425429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132425429&partnerID=8YFLogxK
U2 - 10.1200/JCO.22.00754
DO - 10.1200/JCO.22.00754
M3 - Article
C2 - 35588469
AN - SCOPUS:85132425429
SN - 0732-183X
VL - 111
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 3
ER -
